During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4

被引:35
作者
Basile, Erika [1 ]
Gibbs, Ebrima [1 ]
Aziz, Tariq [1 ]
Oger, Joel [1 ]
机构
[1] Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada
关键词
glatiramer acetate; anti-GA antibodies; IgG1/IgG2/IgG3/IgG4; Th-1/Th-2; IgG secretion in vitro; IgG in serum; primary progressive multiple sclerosis;
D O I
10.1016/j.jneuroim.2006.04.024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study we analyzed the humoral immune response to glatiramer acetate in 16 GA-treated primary progressive MS patients and 9 placebo patients from the PROMiSe study. We have demonstrated that all multiple sclerosis patients (n = 16) continuously treated with GA for 3 years developed anti-GA antibodies that peaked at month 3 and remained elevated during the whole study. We have also demonstrated that initially GA-reactive antibodies of the IgG1 subclass predominate, peaking at month 9 of therapy, but after 9 months IgG1 decreases while anti-GA antibodies of the IgG4 subclass increase and remain high for the 3 years of follow-up. These results support a shift from Th-1 to Th-2 in the antibody response to glatiramer acetate treatment. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 32 条
[31]   Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines:: Implications for multiple sclerosis therapy [J].
Ziemssen, T ;
Kümpfel, T ;
Schneider, H ;
Klinkert, WEF ;
Neuhaus, O ;
Hohlfeld, R .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 233 (1-2) :109-112
[32]   Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF:: implications for multiple sclerosis therapy [J].
Ziemssen, T ;
Kümpfel, T ;
Klinkert, WEF ;
Neuhaus, O ;
Hohlfeld, R .
BRAIN, 2002, 125 :2381-2391